文献速递神经免疫

MOG抗体相关疾病患者临床发作间期MRI新发或增大病灶的频率

Frequency of New or Enlarging Lesions on MRI Outside of Clinical Attacks in Patients With MOG-Antibody-Associated Disease.
PubMed 文献 · Neurology · 2022-10-31

该回顾性研究纳入105例MOG抗体相关疾病(MOGAD)患者共373对无发作间期MRI,发现仅9.5%患者和3%扫描出现新发T2病灶,增强病灶占2%;亚组分析中MOGAD新发脑病灶(4%)低于多发性硬化(54%),与AQP4+视神经脊髓炎谱系疾病(8%)无显著差异。

要点

  • MOGAD临床发作间期新发或增大MRI病灶罕见,仅9.5%患者出现。
  • MOGAD新发脑病灶比例低于多发性硬化,与AQP4+NMOSD无显著差异。
  • MOGAD常规监测MRI的临床效用有限,对试验设计有影响。

核心结论

  • MOGAD在临床发作间期新发或增大MRI病灶罕见,与多发性硬化不同,监测MRI效用有限。

研究设计与样本

  • 回顾性纳入Mayo Clinic的105例MOGAD患者(中位年龄31岁,范围2-80岁;60%女性),共373对基线及随访MRI,无间期发作。
  • 由一名神经科医生和一名神经放射科医生审阅MRI(T2-FLAIR脑、T2脊髓、T1增强脑和脊髓)以识别新发或增大病灶。
  • 选取MOGAD亚组与MS及AQP4+NMOSD患者按大致相似的扫描间隔进行比较。

主要发现

  • 10/105(9.5%)患者和13/373(3%)扫描出现一个或多个新发T2病灶(脑12/213[6%];脊髓1/160[0.6%]);8/367(2%)有增强病灶。
  • 亚组分析中,MOGAD新发脑病灶为1/25(4%),低于MS的14/26(54%)(p < 0.0001)。
  • MOGAD新发脑病灶与AQP4+NMOSD的1/13(8%)无显著差异(p = 1.0)。
  • 各组新发脊髓病灶均罕见(0%-4%)。

临床怎么用

  • 作者认为MOGAD监测MRI效用有限,对临床实践和试验设计有影响。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: To determine the frequency of new or enlarging T2-hyperintense or enhancing lesions outside of clinical attacks in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) vs multiple sclerosis (MS) and aquaporin-4 antibody positive neuromyelitis optica spectrum disorder (AQP4+NMOSD). METHODS: We retrospectively included Mayo Clinic patients with MOGAD with: (1) MOG-Immunoglobulin-G positivity by live cell-based assay, (2) fulfilling proposed MOGAD diagnostic criteria, and (3) baseline and follow-up paired MRIs without interval attacks. A neurologist and neuroradiologist reviewed MRIs (T2-fluid attenuated inversion recovery brain, T2 spine, and T1-postgadolinium brain and spine) to identify new or enlarging lesions. A MOGAD subset was then compared to patients with MS and AQP4+NMOSD, based on broadly similar interscan intervals. RESULTS: We included 105 patients with MOGAD (median age, 31 years [range, 2-80]; 60% female) with 373 paired MRIs. In total, 10/105 (9.5%) patients and 13/373 (3%) scans had one or more new T2 lesions (brain, 12/213 [6%]; spine, 1/160 [0.6%]); and 8/367 (2%) had enhancing lesions. New brain lesions were less in MOGAD (1/25 [4%]) than MS (14/26 [54%], p < 0.0001) but did not differ from AQP4+NMOSD (1/13 [8%], p = 1.0) in subgroup analysis. New spinal lesions were rare across groups (0%-4%). DISCUSSION: New or enlarging MRI lesions rarely develop outside of clinical attacks in MOGAD differing from MS. Surveillance MRIs in MOGAD have limited utility with implications for clinical practice and trial design.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Syc-Mazurek SB, Chen JJ, Morris P, et al. Frequency of New or Enlarging Lesions on MRI Outside of Clinical Attacks in Patients With MOG-Antibody-Associated Disease. Neurology. 2022. PMID: 36175150. doi:10.1212/WNL.0000000000201263

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。